RxDoctor Payments Data

Mojgan Tavakoli, DPM

Podiatrist · Frisco, TXNPI 1801847694

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $51,457 of the $78,780 with a category attached, or 65.3%. Treace Medical Concepts, Inc. accounts for 83.5% of it on its own, with 35 other manufacturers making up the rest. Reporting peaked in 2023 at $35,573 and has fallen 92.4% since, to $2,721 in 2025. Among podiatrist clinicians in TX with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$78,780in general payments, 2019–2025

Across 291 payments — averaging $270.72 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Treace Medical Concepts, Inc.$66K
  • Arthrex$4K
  • Pylant Medical$3K
  • Stryker$1K
  • Medical Device Business Services, Inc.$969
  • Paragon 28, Inc.$831
  • plus $3K from 30 others

What the payments were for

  • Consulting fees$51,45765%
  • Travel & lodging$12,85516%
  • Food & beverage$9,68512%
  • Education$4,7836%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$78,780 in reported general payments places this provider in the 95th percentile of 470 podiatrist providers in Texas.

See all podiatrist providers in Texas

Medicare billing

Part B allowed, 2024
$184,108
Medicare patients
304
Services billed
2,821

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JubliaEfinaconazole18$13,286
EliquisApixaban17$9,434
Tavaborole14$3,256
CiclopiroxCiclopirox Olamine150$2,363
Cephalexin13$515
Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav66$484
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen37$419
Ondansetron OdtOndansetron37$409
Fluconazole29$212
Clindamycin Hcl27$172
Ibuprofen20$139
Celecoxib11$117
Amoxicillin31$112
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen12$101
Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim13$90

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Ortho Dermatologics, A Division Of Bausch Health US, LLCJublia$125$13,28618 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 470 podiatrist providers in Texas.

Other podiatrist in Frisco

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →